The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Checkpoint Therapeutics Inc. defeated investor claims it concealed the likelihood US regulators would deny its skin cancer ...

Macquarie has reaffirmed its ‘outperform’ rating on Sun Pharmaceutical Industries Ltd. and raised its target price to Rs ...

The company also expects R&D spending to rise to 6–8% of sales, reflecting its commitment to pipeline expansion and ...

The company also reported a planned acquisition of its subsidiary Checkpoint Therapeutics by Sun Pharmaceutical ... Fortress’ robust pipeline — including multiple late-stage programs and ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Please see full Prescribing Information. About Checkpoint Therapeutics Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition ...